leadf
logo-loader
viewBiocept Inc

Biocept expands molecular assay offering with release of Target Selector BRAF kit

The test is designed to detect BRAF mutations, among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma

Biocept Inc - Biocept expands molecular assay offering with release of Target Selector BRAF kit
Target Selector kits are a patented liquid biopsy technology that detects and isolates cancer biomarkers

Biocept Inc (NASDAQ:BIOC) has released a new Target Selector molecular assay research-use-only (RUO) kit for clients to use in their own laboratories.

The company, which designs molecular technologies to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, said the kit will help to detect BRAF mutations, among the most frequently evaluated biomarkers across many solid tumor cancers, including lung cancer and melanoma.

READ: Biocept 1Q revenue jumps by double-digits while closing with $21.5M in cash 

Biocept previously launched its molecular assay kit for the detection of EGFR mutations and said it plans to release additional Target Selector molecular assay kits in the future. 

The Target Selector kits are a patented liquid biopsy technology that detects and isolates cancer biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA).

Biocept says its kits offer “superior sensitivity compared with next generation sequencing (NGS) panels for the detection of biomarkers of key oncogene mutations from a blood sample”.

In a statement, Biocept president and chief executive Michael Nall said: "In NGS and many other molecular technology platforms, most of the cost of running an assay is due to analyzing the non-mutated gene of interest, so-called 'wild type' or normal DNA. Our patented Switch-Blocker technology provides the unique ability to block the normal DNA and only analyze the target area of interest.

"Eliminating the cost related to analyzing the wild type DNA makes running a Switch-Blocker-based assay significantly more cost-effective. In the case of NGS panels the costs related to analysis of wild type DNA is compounded, because in these panels approximately 70% or more of the genes are not currently clinically actionable.”

"In international healthcare systems, access to advanced molecular testing for cancer patients can be limited because of cost issues, especially in developing countries. Therefore, we believe that Target Selector molecular assay kits, which offer the combination of a focus on clinically actionable genes, are cost-efficient to run and provide high analytical performance, will be an especially competitive offering", he added.

Contact the author Calum Muirhead at [email protected]

Quick facts: Biocept Inc

Price: 4.63 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $62.01 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

3 weeks, 6 days ago

2 min read